多发性骨髓瘤抗GPRC5D CAR-T细胞治疗后GPRC5D丢失的遗传与表观遗传机制
本研究对10例接受抗GPRC5D CAR-T细胞治疗后复发的多发性骨髓瘤患者样本进行全基因组测序和全基因组亚硫酸氢盐测序,其中8例出现GPRC5D丢失、2例为混合表达(GPRC5D+/-)。3例检出遗传学改变,5例治疗后样本的GPRC5D基因转录调控元件存在多个高甲基化位点;在骨髓瘤细胞系中GPRC5D表达与其调控区甲基化水平呈负相关,阿扎胞苷处理可诱导高甲基化细胞系中GPRC5D信使RNA和蛋白表达。
要点
- 10例抗GPRC5D CAR-T后复发患者中8例GPRC5D丢失、2例混合表达(GPRC5D+/-)。
- 3例检出GPRC5D基因双等位基因失活,5例治疗后样本存在GPRC5D调控元件高甲基化。
- 阿扎胞苷可诱导高甲基化骨髓瘤细胞系中GPRC5D信使RNA和蛋白表达。
核心结论
- 双等位基因遗传失活和高甲基化驱动的表观遗传沉默是导致GPRC5D丢失和治疗耐药的关键机制。
研究设计与样本
- 对10例接受抗GPRC5D CAR-T细胞治疗后复发的多发性骨髓瘤患者样本进行全基因组测序和全基因组亚硫酸氢盐测序,并行骨髓瘤细胞系实验。
主要发现
- 10例患者中8例GPRC5D丢失,2例混合表达(GPRC5D+/-)。
- 3例检出遗传学改变:1例GPRC5D基因纯合缺失,1例GPRC5D调控区双等位基因丢失,1例序贯抗B细胞成熟抗原和抗GPRC5D CAR-T治疗后TNFRSF17和GPRC5D均纯合缺失。
- 其余7例GPRC5D位点未检出遗传学改变,但5例治疗后样本的GPRC5D基因转录调控元件存在多个高甲基化位点。
- 骨髓瘤细胞系中GPRC5D表达与其调控区甲基化水平呈负相关。
- 阿扎胞苷处理可诱导高甲基化骨髓瘤细胞系中GPRC5D信使RNA和蛋白表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
G protein-coupled receptor, class C, group 5, member D (GPRC5D) has emerged as a novel target for chimeric antigen receptor (CAR) T-cell therapy, demonstrating promising efficacy in multiple myeloma (MM). However, disease relapse is still common, and the mechanism of resistance remains poorly understood. In this study, we conducted whole-genome sequencing and whole-genome bisulfite sequencing on MM samples from 10 patients who relapsed after GPRC5D CAR T-cell therapy. Among these patients, 8 had GPRC5D loss, whereas 2 presented mixed expression (GPRC5D+/-). Genetic alterations were identified in 3 cases: one had a homozygous deletion in the GPRC5D gene, another had a biallelic loss in the regulatory regions of GPRC5D, and the third had homozygous deletions in both TNFRSF17 and GPRC5D after sequential anti-B-cell maturation antigen and anti-GPRC5D CAR T-cell therapies. No genetic changes were detected at GPRC5D locus in the remaining 7 cases. However, multiple hypermethylation sites were present in the transcriptional regulatory elements of the GPRC5D gene in 5 post-treatment MM samples. In MM cell lines, GPRC5D expression was inversely correlated with methylation levels in its regulatory regions. Furthermore, azacitidine treatment induced GPRC5D messenger RNA and protein expression in hypermethylated MM cell lines. Our findings highlight that biallelic genetic inactivation and hypermethylation-driven epigenetic silencing are key mechanisms contributing to GPRC5D loss and treatment resistance.
引用
- Ma S, Xia J, Zhang M, et al. Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma. Blood. 2025. PMID: 40090012. doi:10.1182/blood.2024026622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。